BFRGW News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

BF

Mkt Cap

N/A

Volume

938

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

BullFrog AI Unveils bfARENAS™ Scenario-based Decision EngineBullFrog AI Holdings, Inc. (NASDAQ: BFRG) announced the launch of bfARENAS™, a scenario-based decision engine designed to help biotech and pharmaceutical companies optimize drug portfolio strategy and clinical trial design. The new tool completes the company's end-to-end AI intelligence workflow by enabling head-to-head comparison of drug programs across multiple strategic scenarios, addressing the industry challenge where approximately 90% of clinical trials fail due to inefficient capital deployment and lack of structured decision-making frameworks.GlobeNewswire Inc. · Mar 25, 2026

ProFound Therapeutics Strengthens Leadership Team with Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources OfficerProFound Therapeutics appointed Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources Officer to enhance their AI-driven drug discovery platform and organizational capabilities.GlobeNewswire Inc. · Dec 18, 2025

BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma ClientsBullFrog AI, a technology-enabled drug development company, announced a strategic collaboration with Sygnature Discovery, a UK-based contract research organization. Through this collaboration, Sygnature will introduce BullFrog's AI-driven data insights platform, BullFrog Data Networks™, to its global biopharma client base.GlobeNewswire Inc. · Jun 12, 2025

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on June 12GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET.GlobeNewswire Inc. · May 29, 2024

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber InstituteGAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat. This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).GlobeNewswire Inc. · Mar 8, 2024

BullFrog AI Announces Underwriter’s Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company’s Common StockGAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter’s decision to exercise their over-allotment option to purchase 218,382 shares of the Company’s common stock (the “Option Shares”), pursuant to the Underwriting Agreement, dated January 31, 2024, by and between BullFrog AI Holdings, Inc. and WallachBeth Capital, LLC as representative of the Underwriters (the “Underwriting Agreement”).GlobeNewswire Inc. · Feb 21, 2024

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChipGAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.GlobeNewswire Inc. · Feb 9, 2024

BullFrog AI Announces Closing of $5.7 Million Public OfferingGAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the closing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.GlobeNewswire Inc. · Feb 5, 2024

Bullfrog AI Announces Pricing of $5.7 Million Public OfferingGAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.GlobeNewswire Inc. · Feb 1, 2024

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah WalaGAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of two distinguished scientific advisors to its advisory board: Gwenn S. Smith, PhD, and Jeremiah Wala, MD, PhD.GlobeNewswire Inc. · Jan 26, 2024

BF

BFRGWBullfrog AI Holdings, Inc. Warrants

BFRGW

Pay with—

Available Balance0.00

Your PositionYou don't own any BFRGW yet.

Related Tickers

Earnings